Biogen, Inc. is a biopharmaceutical company focused on the development and manufacturing of therapies for neurology, immunology, and other healthcare ...Read more
5,000 - 9,999
BIIB
biogen.com
Public
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Biogen, Inc.
Are you looking for the decision-makers at Biogen, Inc.? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Biogen, Inc.’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDiscover Biogen, Inc. alternatives or similar companies to benchmark and competitors market analysis. Build a competitive intelligence sales and marketing strategy based on the data and stand out in the market.
Rachel Sanders
0 - 9
Newton
N/A
N/A
N/A
1751 Web Design, LLC
0 - 9
Newton
1751webdesign.com
Private
N/A
Ink Inc. Publishing Services
20 - 49
Newton
inkincpub.com
N/A
N/A
N/A
NAMI Lewistown
5,000 - 9,999
San Francisco
namilewistown.wordpress.com
N/A
N/A
N/A
H&M Hennes & Mauritz AB
10,000+
Stockholm
hm.com
Public
N/A
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Biogen, Inc. latest news, alerts and updates.
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen‚ rare disease portfolio with the addition of SKYCLARYS¬Æ (omaveloxolone), the first and only FDA approved treatment for Friedreich‚ataxia in the U.S. CAMBRIDGE, Mass.
26 Sep 2023
Reata Pharma Stockholders Approve Acquisition By Biogen
Reata Pharmaceuticals Inc. (RETA) said that its stockholders have approved the company's previously announced acquisition by Biogen
21 Sep 2023
Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Click here to read more.
11 Aug 2023
Biogen to acquire Reata for approximately $7.3bn
This is a unique opportunity for Biogen to bolster our near term growth trajectory, and Skyclarys is an excellent complement to our global portfolio of treatments for neuromuscular and rare disease. Warren Huff,
3 Aug 2023
Biogen to Acquire Plano-Based Biotech Reata Pharmaceuticals
Plano-based global biotech company Reata Pharmaceuticals Inc. is being acquired by Biogen Inc. in a deal valued at roughly $7.3 billion. It's an all-cash deal for $172.50 per share, the companies said.
28 Jul 2023
Biogen Announces Changes to Its Board of Directors
Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., (GLOBE NEWSWIRE) -- Biogen
12 Jun 2023
Explore frequently asked questions about Biogen, Inc.’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
What is Biogen, Inc.'s official website?
The official website of Biogen, Inc. is biogen.com You can find their contact number, email address, and headquarters by clicking here.
How many employees are working at Biogen, Inc.?
What industry is Biogen, Inc. in?
What is Biogen, Inc.'s tech stack?
Where are Biogen, Inc.'s headquarters?